Venture capitalist Jon Moulton has backed Infex Therapeutics, a biotech firm based in Alderley Edge, which is working to address the “critical global threat” of antibiotic-resistant infections. The company has successfully secured £4.3 million in a funding round led by Mr. Moulton, alongside the GM&C Life Sciences Fund managed by Catapult Ventures and existing high net worth investors.
Funding to Combat Antimicrobial Resistance
The newly acquired funds will be directed towards advancing Infex Therapeutics’ pipeline of novel anti-infectives designed to combat antimicrobial resistance (AMR) and other “critical-priority infectious diseases.” This investment marks a significant step in the fight against drug-resistant infections, which pose a growing danger to global health.
Dr. Peter Jackson, CEO of Infex Therapeutics, expressed his enthusiasm: “We are delighted to secure this investment led by Jon Moulton, with support from the Greater Manchester and Cheshire Lifescience Investment Fund and our existing investors. This funding represents strong validation of our progress in developing novel anti-infectives to address the critical global threat of antimicrobial resistance.”
Jon Moulton’s Continued Support
Jon Moulton, founder of Better Capital and now chair of Infex Therapeutics, highlighted the company’s progress: “We have supported Infex from the beginning and continue to be impressed by the company’s scientific progress and strategic execution.” He specifically noted Infex’s lead programme RESP-X, which is currently being trialled as a therapy for patients with non-cystic fibrosis bronchiectasis (NCFB). Moulton added: “This additional investment reflects our strong conviction in both the team and its innovative approach to tackling antimicrobial resistance.”
Recognition from Investors
Nick Wright, CEO of Catapult Ventures, which manages the GM&C Life Sciences Fund, praised the company’s achievements: “Infex Therapeutics has made excellent scientific progress since we first invested several years ago. The company has clearly established itself as a world leader in the AMR and related space, and the data it is generating is very compelling.”
With this new funding, Infex Therapeutics is poised to accelerate its research and development efforts, bringing much-needed therapies closer to patients battling resistant infections.
